Drug intelligence / Profile preview

Chinese Medicine Oral Rinse Formula-I

Development stage: Phase 2
Lead developer: The Chinese University of Hong Kong
Modality: Small Molecules
Administration: Topical

Overview

Chinese Medicine Oral Rinse Formula-I (CMORF-I) is an investigational herbal formulation developed by the Chinese University of Hong Kong for the prevention and treatment of radiation-induced oral mucositis in patients with head and neck cancer. Administered as a topical oral rinse reconstituted from concentrated granules, CMORF-I is designed to mitigate the dose-limiting mucosal damage associated with radiotherapy and chemoradiotherapy. The formula likely utilizes the anti-inflammatory and tissue-healing properties of traditional Chinese medicinal herbs to reduce symptom severity and improve patient quality of life during cancer treatment.

Other names: Chinese Medicine Oral Rinse Formula-ICMORF-I

Beyond the preview

Go deeper on Chinese Medicine Oral Rinse Formula-I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chinese Medicine Oral Rinse Formula-I.

Explore the full profile